MEDP vs ICLR stock comparison
Medpace vs. Icon · data as of November 13, 2026
Medpace (MEDP) has a market value of about $18.3B, Icon (ICLR) about $14.9B. Over their latest twelve months Medpace had revenue of $2.8B and Icon $8.2B.
On our five checks Medpace scores higher: 3.2 out of 5 (average) against 1.8 (weak).
By area, the stronger company is Medpace on future growth; Medpace on track record; Medpace on financial health.
Medpace is cheaper on earnings (P/E 36.3 vs. 77.9), while Icon grew revenue faster over five years (24.1% vs. 22.3% a year).
Medpace leads on 11 of the compared lines and Icon on 8.
Side by side
| MEDP | ICLR | |
|---|---|---|
| Size and price | ||
| Market cap | $18.3B | $14.9B |
| Share price | $653.94 | $194.65 |
| Score | ||
| Overall score (of 5) | 3.2 | 1.8 |
| Value | 1 | 1 |
| Future growth | 4 | 1 |
| Track record | 5 | 2 |
| Financial health | 4 | 3 |
| Shareholder returns | 2 | 2 |
| Valuation | ||
| P/E (TTM) | 36.3 | 77.9 |
| Forward P/E | 33.6 | 17.2 |
| Price / free cash flow | 27.4 | 17.4 |
| Price / sales | 6.4 | 1.8 |
| EV / EBITDA | 27.9 | 36.1 |
| PEG | 1.14 | — |
| DCF value vs. price | −32% | −27% |
| Business | ||
| Revenue | $2.8B | $8.2B |
| Net income | $518M | $449M |
| Free cash flow | $668M | $857M |
| Net margin | 18.2% | 5.4% |
| Gross margin (5-yr avg.) | — | 28.4% |
| ROIC (5-yr avg.) | 41.9% | 4.9% |
| Growth | ||
| Revenue growth (1 yr) | 20.0% | 0.8% |
| Revenue growth (5 yrs, per year) | 22.3% | 24.1% |
| EPS growth (5 yrs, per year) | 31.8% | -14.0% |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | — | -$2.7B |
| Dividend yield | None | None |
| Shareholder yield | 5.0% | 5.0% |
| Analysts | ||
| Upside to average target | −0% | +19% |
| Consensus rating | none | Buy |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: MEDP TTM to September 30, 2026, ICLR TTM to September 30, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, Medpace or Icon?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Medpace scores 3.2 out of 5 and Icon 1.8; the table shows where each one is stronger.
Is Medpace cheaper than Icon?
On trailing earnings, Medpace trades at a P/E of 36.3 and Icon at 77.9, so Medpace is cheaper by this measure. A lower P/E can also reflect slower expected growth.
Which grows faster, Medpace or Icon?
Over five years Icon grew revenue about 24.1% a year and Medpace about 22.3% a year.
Full Medpace analysis → Full Icon analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.